{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:07:21Z","timestamp":1791299241492,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,10,12]],"date-time":"2015-10-12T00:00:00Z","timestamp":1444608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2015,10,12]],"date-time":"2015-10-12T00:00:00Z","timestamp":1444608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>With up to 500,000 infections annually, Lassa virus (LASV), the cause of Lassa fever, is one of the most prevalent etiological agents of viral hemorrhagic fever (VHF) in humans. LASV is endemic in several West African countries with sporadic cases and prolonged outbreaks observed most commonly in Sierra Leone, Liberia, Guinea and Nigeria. Additionally several cases of Lassa fever have been imported into North America, Europe and Asia making LASV a global threat to public health. Despite this, currently no approved therapeutic or vaccine exists to treat or prevent LASV infections. Here, using a passaged strain of LASV that is uniformly lethal in Hartley guinea pigs, we demonstrate that favipiravir, a broad-spectrum antiviral agent and leading treatment option for influenza, has potent activity against LASV infection. In this model, once daily treatment with favipiravir significantly reduced viral titers in tissue samples and reduced mortality rates when compared with animals receiving vehicle-only or ribavirin, the current standard of care for Lassa fever. Favipiravir remained highly effective against lethal LASV infection when treatments were initiated nine days post-infection, a time when animals were demonstrating advanced signs of disease. These results support the further preclinical evaluation of favipiravir for Lassa fever and other VHFs.<\/jats:p>","DOI":"10.1038\/srep14775","type":"journal-article","created":{"date-parts":[[2015,10,12]],"date-time":"2015-10-12T04:52:11Z","timestamp":1444625531000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":131,"title":["The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset"],"prefix":"10.1038","volume":"5","author":[{"given":"David","family":"Safronetz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle","family":"Rosenke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonna B.","family":"Westover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Martellaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousuke","family":"Furuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Geisbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Saturday","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Komeno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Geisbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian B.","family":"Gowen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,12]]},"reference":[{"key":"BFsrep14775_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.coviro.2013.04.007","volume":"3","author":"D Falzarano","year":"2013","unstructured":"Falzarano, D. & Feldmann, H. Vaccines for viral hemorrhagic fevers-progress and shortcomings. Current opinion in virology 3, 343\u2013351, 10.1016\/j.coviro.2013.04.007 (2013).","journal-title":"Current opinion in virology"},{"key":"BFsrep14775_CR2","first-page":"75","volume":"262","author":"JB McCormick","year":"2002","unstructured":"McCormick, J. B. & Fisher-Hoch, S. P. Lassa fever. Current topics in microbiology and immunology 262, 75\u2013109 (2002).","journal-title":"Current topics in microbiology and immunology"},{"key":"BFsrep14775_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1093\/infdis\/155.3.445","volume":"155","author":"JB McCormick","year":"1987","unstructured":"McCormick, J. B. et al. A case-control study of the clinical diagnosis and course of Lassa fever. The Journal of infectious diseases 155, 445\u2013455 (1987).","journal-title":"The Journal of infectious diseases"},{"key":"BFsrep14775_CR4","first-page":"69","volume":"134","author":"JB McCormick","year":"1987","unstructured":"McCormick, J. B. Epidemiology and control of Lassa fever. Current topics in microbiology and immunology 134, 69\u201378 (1987).","journal-title":"Current topics in microbiology and immunology"},{"key":"BFsrep14775_CR5","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/bmj.311.7009.857","volume":"311","author":"SP Fisher-Hoch","year":"1995","unstructured":"Fisher-Hoch, S. P. et al. Review of cases of nosocomial Lassa fever in Nigeria: the high price of poor medical practice. Bmj 311, 857\u2013859 (1995).","journal-title":"Bmj"},{"key":"BFsrep14775_CR6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1126\/science.185.4147.263","volume":"185","author":"TP Monath","year":"1974","unstructured":"Monath, T. P., Newhouse, V. F., Kemp, G. E., Setzer, H. W. & Cacciapuoti, A. Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science 185, 263\u2013265 (1974).","journal-title":"Science"},{"key":"BFsrep14775_CR7","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1863-2378.2012.01469.x","volume":"59","author":"N Sogoba","year":"2012","unstructured":"Sogoba, N., Feldmann, H. & Safronetz, D. Lassa fever in West Africa: evidence for an expanded region of endemicity. Zoonoses and public health 59 Suppl 2, 43\u201347, 10.1111\/j.1863-2378.2012.01469.x (2012).","journal-title":"Zoonoses and public health"},{"key":"BFsrep14775_CR8","doi-asserted-by":"publisher","first-page":"e2582","DOI":"10.1371\/journal.pntd.0002582","volume":"7","author":"D Safronetz","year":"2013","unstructured":"Safronetz, D. et al. Geographic distribution and genetic characterization of Lassa virus in sub-Saharan Mali. PLoS neglected tropical diseases 7, e2582, 10.1371\/journal.pntd.0002582 (2013).","journal-title":"PLoS neglected tropical diseases"},{"key":"BFsrep14775_CR9","doi-asserted-by":"publisher","first-page":"e388","DOI":"10.1371\/journal.pntd.0000388","volume":"3","author":"E Fichet-Calvet","year":"2009","unstructured":"Fichet-Calvet, E. & Rogers, D. J. Risk maps of Lassa fever in West Africa. PLoS neglected tropical diseases 3, e388, 10.1371\/journal.pntd.0000388 (2009).","journal-title":"PLoS neglected tropical diseases"},{"key":"BFsrep14775_CR10","doi-asserted-by":"publisher","first-page":"466","DOI":"10.3201\/eid0605.000504","volume":"6","author":"S Gunther","year":"2000","unstructured":"Gunther, S. et al. Imported lassa fever in Germany: molecular characterization of a new lassa virus strain. Emerging infectious diseases 6, 466\u2013476, 10.3201\/eid0605.000504 (2000).","journal-title":"Emerging infectious diseases"},{"key":"BFsrep14775_CR11","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3201\/eid1205.050052","volume":"12","author":"AM Macher","year":"2006","unstructured":"Macher, A. M. & Wolfe, M. S. Historical Lassa fever reports and 30-year clinical update. Emerging infectious diseases 12, 835\u2013837, 10.3201\/eid1205.050052 (2006).","journal-title":"Emerging infectious diseases"},{"key":"BFsrep14775_CR12","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJM198601023140104","volume":"314","author":"JB McCormick","year":"1986","unstructured":"McCormick, J. B. et al. Lassa fever. Effective therapy with ribavirin. The New England journal of medicine 314, 20\u201326, 10.1056\/NEJM198601023140104 (1986).","journal-title":"The New England journal of medicine"},{"key":"BFsrep14775_CR13","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","volume":"49","author":"Y Furuta","year":"2005","unstructured":"Furuta, Y. et al. Mechanism of action of T-705 against influenza virus. Antimicrobial agents and chemotherapy 49, 981\u2013986, 10.1128\/AAC.49.3.981-986.2005 (2005).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep14775_CR14","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1073\/pnas.0909603107","volume":"107","author":"M Kiso","year":"2010","unstructured":"Kiso, M. et al. T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proceedings of the National Academy of Sciences of the United States of America 107, 882\u2013887, 10.1073\/pnas.0909603107 (2010).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep14775_CR15","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.antiviral.2009.02.198","volume":"82","author":"Y Furuta","year":"2009","unstructured":"Furuta, Y. et al. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral research 82, 95\u2013102, 10.1016\/j.antiviral.2009.02.198 (2009).","journal-title":"Antiviral research"},{"key":"BFsrep14775_CR16","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1128\/AAC.01739-09","volume":"54","author":"K Sleeman","year":"2010","unstructured":"Sleeman, K. et al. In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrobial agents and chemotherapy 54, 2517\u20132524, 10.1128\/AAC.01739-09 (2010).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep14775_CR17","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","volume":"100","author":"Y Furuta","year":"2013","unstructured":"Furuta, Y. et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral research 100, 446\u2013454, 10.1016\/j.antiviral.2013.09.015 (2013).","journal-title":"Antiviral research"},{"key":"BFsrep14775_CR18","doi-asserted-by":"publisher","first-page":"193","DOI":"10.3851\/IMP1729","volume":"21","author":"KK Buys","year":"2011","unstructured":"Buys, K. K., Jung, K. H., Smee, D. F., Furuta, Y. & Gowen, B. B. Maporal virus as a surrogate for pathogenic New World hantaviruses and its inhibition by favipiravir. Antiviral chemistry & chemotherapy 21, 193\u2013200, 10.3851\/IMP1729 (2011).","journal-title":"Antiviral chemistry & chemotherapy"},{"key":"BFsrep14775_CR19","doi-asserted-by":"publisher","first-page":"4673","DOI":"10.1128\/AAC.00886-13","volume":"57","author":"D Safronetz","year":"2013","unstructured":"Safronetz, D. et al. Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimicrobial agents and chemotherapy 57, 4673\u20134680, 10.1128\/AAC.00886-13 (2013).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep14775_CR20","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1128\/AAC.01219-10","volume":"55","author":"M Mendenhall","year":"2011","unstructured":"Mendenhall, M. et al. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrobial agents and chemotherapy 55, 782\u2013787, 10.1128\/AAC.01219-10 (2011).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep14775_CR21","doi-asserted-by":"publisher","first-page":"e1342","DOI":"10.1371\/journal.pntd.0001342","volume":"5","author":"M Mendenhall","year":"2011","unstructured":"Mendenhall, M. et al. Effective oral favipiravir (T-705) therapy initiated after the onset of clinical disease in a model of arenavirus hemorrhagic Fever. PLoS neglected tropical diseases 5, e1342, 10.1371\/journal.pntd.0001342 (2011).","journal-title":"PLoS neglected tropical diseases"},{"key":"BFsrep14775_CR22","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1128\/AAC.01074-08","volume":"53","author":"JG Julander","year":"2009","unstructured":"Julander, J. G., Shafer, K., Smee, D. F., Morrey, J. D. & Furuta, Y. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrobial agents and chemotherapy 53, 202\u2013209, 10.1128\/AAC.01074-08 (2009).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep14775_CR23","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.antiviral.2009.02.201","volume":"82","author":"JG Julander","year":"2009","unstructured":"Julander, J. G., Smee, D. F., Morrey, J. D. & Furuta, Y. Effect of T-705 treatment on western equine encephalitis in a mouse model. Antiviral research 82, 169\u2013171, 10.1016\/j.antiviral.2009.02.201 (2009).","journal-title":"Antiviral research"},{"key":"BFsrep14775_CR24","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.bbrc.2012.07.034","volume":"424","author":"J Rocha-Pereira","year":"2012","unstructured":"Rocha-Pereira, J. et al. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochemical and biophysical research communications 424, 777\u2013780, 10.1016\/j.bbrc.2012.07.034 (2012).","journal-title":"Biochemical and biophysical research communications"},{"key":"BFsrep14775_CR25","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1128\/AAC.46.4.977-981.2002","volume":"46","author":"Y Furuta","year":"2002","unstructured":"Furuta, Y. et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrobial agents and chemotherapy 46, 977\u2013981 (2002).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep14775_CR26","doi-asserted-by":"publisher","first-page":"e3725","DOI":"10.1371\/journal.pone.0003725","volume":"3","author":"BB Gowen","year":"2008","unstructured":"Gowen, B. B. et al. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PloS one 3, e3725, 10.1371\/journal.pone.0003725 (2008).","journal-title":"PloS one"},{"key":"BFsrep14775_CR27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/1743-422X-7-240","volume":"7","author":"BB Gowen","year":"2010","unstructured":"Gowen, B. B. et al. Assessing changes in vascular permeability in a hamster model of viral hemorrhagic fever. Virology journal 7, 240, 10.1186\/1743-422X-7-240 (2010).","journal-title":"Virology journal"},{"key":"BFsrep14775_CR28","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.antiviral.2014.01.012","volume":"104","author":"SJ Smither","year":"2014","unstructured":"Smither, S. J. et al. Post-exposure efficacy of oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral research 104, 153\u2013155, 10.1016\/j.antiviral.2014.01.012 (2014).","journal-title":"Antiviral research"},{"key":"BFsrep14775_CR29","doi-asserted-by":"publisher","first-page":"e2804","DOI":"10.1371\/journal.pntd.0002804","volume":"8","author":"L Oestereich","year":"2014","unstructured":"Oestereich, L. et al. Evaluation of antiviral efficacy of ribavirin, arbidol and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. PLoS neglected tropical diseases 8, e2804, 10.1371\/journal.pntd.0002804 (2014).","journal-title":"PLoS neglected tropical diseases"},{"key":"BFsrep14775_CR30","unstructured":"Efficacy of favipiravir against Ebola (JIKI), &lt; https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02329054&gt; (2014). Date of access: 26\/05\/2015."},{"key":"BFsrep14775_CR31","doi-asserted-by":"publisher","first-page":"e2614","DOI":"10.1371\/journal.pntd.0002614","volume":"7","author":"BB Gowen","year":"2013","unstructured":"Gowen, B. B. et al. Favipiravir (T-705) inhibits Junin virus infection and reduces mortality in a guinea pig model of Argentine hemorrhagic fever. PLoS neglected tropical diseases 7, e2614, 10.1371\/journal.pntd.0002614 (2013).","journal-title":"PLoS neglected tropical diseases"},{"key":"BFsrep14775_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.antiviral.2014.10.001","volume":"112","author":"DR Smith","year":"2014","unstructured":"Smith, D. R., Holbrook, M. R. & Gowen, B. B. Animal models of viral hemorrhagic fever. Antiviral research 112, 59\u201379, 10.1016\/j.antiviral.2014.10.001 (2014).","journal-title":"Antiviral research"},{"key":"BFsrep14775_CR33","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1128\/iai.37.2.771-778.1982","volume":"37","author":"PB Jahrling","year":"1982","unstructured":"Jahrling, P. B., Smith, S., Hesse, R. A. & Rhoderick, J. B. Pathogenesis of Lassa virus infection in guinea pigs. Infection and immunity 37, 771\u2013778 (1982).","journal-title":"Infection and immunity"},{"key":"BFsrep14775_CR34","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/infdis\/jit004","volume":"207","author":"D Safronetz","year":"2013","unstructured":"Safronetz, D. et al. A recently isolated lassa virus from mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques. The Journal of infectious diseases 207, 1316\u20131327, 10.1093\/infdis\/jit004 (2013).","journal-title":"The Journal of infectious diseases"},{"key":"BFsrep14775_CR35","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.antiviral.2011.02.012","volume":"90","author":"KA Cashman","year":"2011","unstructured":"Cashman, K. A. et al. Evaluation of Lassa antiviral compound ST-193 in a guinea pig model. Antiviral research 90, 70\u201379, 10.1016\/j.antiviral.2011.02.012 (2011).","journal-title":"Antiviral research"},{"key":"BFsrep14775_CR36","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","volume":"22","author":"S Reagan-Shaw","year":"2008","unstructured":"Reagan-Shaw, S., Nihal, M. & Ahmad, N. Dose translation from animal to human studies revisited. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 22, 659\u2013661, 10.1096\/fj.07-9574LSF (2008).","journal-title":"FASEB journal: official publication of the Federation of American Societies for Experimental Biology"},{"key":"BFsrep14775_CR37","first-page":"631","volume":"57","author":"H Wulff","year":"1979","unstructured":"Wulff, H. & Johnson, K. M. Immunoglobulin M and G responses measured by immunofluorescence in patients with Lassa or Marburg virus infections. Bulletin of the World Health Organization 57, 631\u2013635 (1979).","journal-title":"Bulletin of the World Health Organization"},{"key":"BFsrep14775_CR38","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1128\/AAC.00356-07","volume":"51","author":"BB Gowen","year":"2007","unstructured":"Gowen, B. B. et al. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrobial agents and chemotherapy 51, 3168\u20133176, 10.1128\/AAC.00356-07 (2007).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"BFsrep14775_CR39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/1743-422X-8-205","volume":"8","author":"LE Hensley","year":"2011","unstructured":"Hensley, L. E. et al. Pathogenesis of Lassa fever in cynomolgus macaques. Virology journal 8, 205, 10.1186\/1743-422X-8-205 (2011).","journal-title":"Virology journal"},{"key":"BFsrep14775_CR40","doi-asserted-by":"publisher","first-page":"e0003736","DOI":"10.1371\/journal.pntd.0003736","volume":"9","author":"D Safronetz","year":"2015","unstructured":"Safronetz, D. et al. A Recombinant Vesicular Stomatitis Virus-Based Lassa Fever Vaccine Protects Guinea Pigs and Macaques against Challenge with Geographically and Genetically Distinct Lassa Viruses. PLoS neglected tropical diseases 9, e0003736, 10.1371\/journal.pntd.0003736 (2015).","journal-title":"PLoS neglected tropical diseases"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep14775.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep14775","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep14775.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T11:07:58Z","timestamp":1672916878000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep14775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,12]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2015,12,7]]}},"alternative-id":["BFsrep14775"],"URL":"https:\/\/doi.org\/10.1038\/srep14775","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,12]]},"assertion":[{"value":"19 June 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.F. and T.K. are employees of the Toyama Chemical Co., Ltd., the manufacturer of favipiravir. All other authors declare that no competing interests exist.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14775"}}